Well Health Provides Vague Preliminary Q4 Results, Announces Return Of Buyback Program
Well Health (TSX: WELL) is looking to boost its share price. The firm this morning published preliminary earnings for the fourth quarter, indicating that its current revenue run rate exceeds the prior guidance of “exceeding $450 million” on an annualized basis.
In addition to the revenue run rate exceeding $450 million, the company also indicated that its adjusted EBITDA run rate for the year should be exceeding $100 million as well. The quarter reportedly had “strong organic growth,” which came from both virtual services and omni-channel patient services.
Further details on financial results for the fourth quarter were not provided. However, the company did indicate that it had a total of 692,913 omni-channel visits in the quarter, along with 146,116 diagnostic visits for MyHealth and 126,265 patient consultations.
The company also indicated this morning that it will be “re-activating” its normal course issuer bid announced last April, a result of the firms share price falling dramatically in recent weeks. The program is slated to be re-activated following the release of its 2021 financial results.
Well Health last traded at $3.83 on the TSX.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
